Allison Bartlett to Infliximab
This is a "connection" page, showing publications Allison Bartlett has written about Infliximab.
Connection Strength
0.166
-
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemp Clin Trials. 2019 04; 79:98-103.
Score: 0.141
-
A 12-week-old male with a 10-day history of fever. Pediatr Ann. 2014 May; 43(5):e111-5.
Score: 0.025